Showing 2081-2090 of 8649 results for "".
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial-2/2479337/Nicox SA announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase, as well as the required two-week, follow-up period. Top-line results are expected to be announced in September 2021. “The Phase 2b Missis
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479335/Nicox SA announced that the last patient in the NCX 4251 Mississippi phase 2b blepharitis clinical trial has now completed the 2-week treatment phase as well as the required 2-week follow up period. Topline results are expected to be announced in September 20
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotechhttps://modernod.com/news/arnaud-lacoste-is-named-chief-scientific-officer-of-aurion-biotech/2479293/Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies. Arnaud will lead R&D teams based in Boston and Seattle. “Arnaud is a brilliant scientist, a strategic e
- VSY Biotechnology Announces Launch of the Enova C Haptic Model IOLhttps://modernod.com/news/vsy-biotechnology-announces-launch-of-the-enova-c-haptic-model-iol/2479260/VSY Biotechnology announced the launch of the Enova C Haptic Model IOL. Enova is the first and only 100% glistening-free, dry-packed hydrophobic acrylic IOL, according to VSY Biotechnology. The lens requires no warming or special conditioning before surgery. The composition of Enova mater
- Avellino Launches AvaGen as First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophieshttps://modernod.com/news/avellino-launches-avagen-as-first-genetic-test-to-quantify-keratoconus-risk-and-presence-of-corneal-dystrophies/2479255/Avellino Lab USA announced full nationwide availability in the US of AvaGen, as the first genetic test that helps determine a patient’s risk of keratoconus and the presence of other corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions
- Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring Apphttps://modernod.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/Tilak Healthcare is launching a pilot program in the US with Novartis for OdySight, Tilak’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (
- Nicox’s Licensee Bausch + Lomb Launches Vyzulta in Taiwan and Receives Approval in Qatarhttps://modernod.com/news/nicoxs-licensee-bausch-lomb-launches-vyzulta-in-taiwan-and-receives-approval-in-qatar/2479163/Nicox SA announced that its exclusive global licensee Bausch + Lomb has launched Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. Vyzulta has also recently received approval in Qatar. In addition to Taiwan, Vyzul
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro